Macrogenics Inc

Research Macrogenics Inc (MGNX) on Bullrun: market cap USD 265.40M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 265.40M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 149.50M-USD 74.62K-USD 82.95M100.0%-1.18USD 57.22MUSD 36.76MUSD 55.59M
FY2024USD 149.96M-USD 66.97K-USD 72.08M99.4%-1.07USD 182.84MUSD 37.46MUSD 116.06M
FY2023USD 58.75M-USD 9.06K-USD 79.97M98.9%-0.15USD 100.96MUSD 33.97MUSD 152.61M
FY2022USD 151.94M-USD 119.76M-USD 90.58M97.8%-1.95USD 108.88MUSD 23.20MUSD 142.01M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 265.40Mn/an/an/a
20252025-12-31USD 101.94Mn/an/an/a
20242024-12-31USD 204.16Mn/an/an/a
20232023-12-29USD 596.72M12.0n/an/a
20222022-12-30USD 412.50Mn/an/an/a
20212021-12-31USD 983.98Mn/an/an/a

About Macrogenics Inc

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Macrogenics Inc's market cap?

Macrogenics Inc's market capitalization is USD 265.40M.

What does Macrogenics Inc do?

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.